Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 20
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Chemomab Therapeutics Ltd
CMMB
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.22
0.05
4.27%
Ult. Agg.: Oct 20, 10:58 AM
$1.20
0.03
2.56%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Privacy Manager
Chemomab Therapeutics Financials
Chemomab Therapeutics (CMMB) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
CORRECTION: Chemomab Therapeutics Q2 EPADS $(0.27) Misses $(0.15) Estimate
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.15) by 80 percent. This is a 25 percent increase over losses of $(0.36) per share
Benzinga Newsdesk
PRO
Chemomab Therapeutics Q1 EPS $(0.24) Beats $(0.31) Estimate
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.31) by 22.58 percent. This is a 57.14 percent increase over losses of $(0.56) per share
Benzinga Newsdesk
PRO
Chemomab Therapeutics Q4 EPS $(0.24) Beats $(0.40) Estimate
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.40) by 40 percent. This is a 62.5 percent increase over losses of $(0.64) per share from
Benzinga Newsdesk
PRO
Chemomab Therapeutics Q3 EPS $(0.28) Beats $(0.40) Estimate
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.40) by 30 percent. This is a 65 percent increase over losses of $(0.80) per share from
Benzinga Newsdesk
PRO
CORRECTION: Chemomab Therapeutics Q2 EPADS $(0.09) Misses $(0.07) Estimate
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 20 percent. This is a 592.31 percent decrease over losses of $(0.01) per share
Benzinga Newsdesk
PRO
UPDATE: Chemomab Therapeutics Q1 EPADS $(0.14) Misses $(0.10) Estimate
Benzinga Newsdesk
